Bellus Health Inc Stock Price, News & Analysis

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) announced that an abstract from the Phase 2b SOOTHE trial will be presented at the CHEST Annual Meeting from October 16-19, 2022. The presentation details prior consultations and treatments in patients with refractory chronic cough (RCC). The company's product BLU-5937, aimed at RCC, has completed Phase 2b trials and is preparing for the CALM Phase 3 program in Q4 2022. RCC affects about 9 million patients in the U.S., with significant quality of life impacts and limited treatment options available.

BELLUS Health Inc. (NASDAQ:BLU) announced that CEO Roberto Bellini will present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 7:00 a.m. ET. This presentation will include an update on the Company's pipeline, particularly the Phase 2b trial results of its product candidate, BLU-5937, aimed at treating refractory chronic cough (RCC). Following the event, a recorded webcast will be available on the Company's website, which is focused on developing innovative therapies for cough hypersensitivity indications.

BELLUS Health has announced the presentation of three abstracts from the Phase 2b SOOTHE trial at the European Respiratory Society International Congress 2022 in Barcelona, Spain, on September 4. The abstracts focus on participant characteristics, efficacy, and improvements in cough frequency with BLU-5937, a potential treatment for refractory chronic cough (RCC). The company plans to initiate the CALM Phase 3 program for BLU-5937 in Q4 2022. Currently, no specific therapies are approved for RCC in the US, highlighting a significant unmet medical need.

BELLUS Health Inc. (NASDAQ:BLU) announced positive outcomes from its End-of-Phase 2 meeting with the FDA and received scientific advice from the EMA for its CALM Phase 3 program, targeting refractory chronic cough (RCC) with its candidate, BLU-5937. The company ended Q2 2022 with pro-forma cash of approximately US$384.6 million, extending its cash runway to 2025. They completed a successful US$176 million public offering and plan to initiate pivotal trials CALM-1 and CALM-2 in Q4 2022, with topline results expected in 2024.

BELLUS Health has completed its underwritten public offering of 16,540,541 common shares at US$9.25 each, generating US$153 million in gross proceeds. The company plans to use the net proceeds to fund research and development activities for its product candidate, BLU-5937, alongside working capital and general corporate needs. The offering included a 30-day option for underwriters to purchase an additional 2,481,081 shares. The company’s shares are dual-listed on Nasdaq and the Toronto Stock Exchange under the symbol BLU.

BELLUS Health announced a public offering of 16,540,541 common shares priced at US$9.25 each, expecting to close on July 18, 2022. The underwriters include Jefferies, Evercore ISI, and RBC Capital Markets, with an option for an additional 2,481,081 shares. Proceeds will primarily fund research and development for BLU-5937, addressing refractory chronic cough and related disorders. This offering follows previous prospectus filings dated December 2021 and December 2020.

BELLUS Health has filed a preliminary prospectus supplement for a proposed public offering of its common shares. This follows the amended and restated short form base shelf prospectus dated December 14, 2021. The offering aims to generate funds primarily for research and development of its product candidate, BLU-5937, along with other corporate needs. The underwriters may purchase up to an additional 15% of common shares. The offering will depend on market conditions and regulatory approvals from the Toronto Stock Exchange.

BELLUS Health announced a successful End-of-Phase 2 meeting with the FDA regarding its investigational product BLU-5937 for refractory chronic cough (RCC). The CALM Phase 3 program will feature two pivotal trials, CALM-1 and CALM-2, aiming to enroll around 675 adults. Key endpoints include assessing 24-hour cough frequency at 12 and 24 weeks. The first patient is expected to be enrolled in Q4 2022, with topline results from CALM-1 anticipated in 2H 2024. This represents a crucial step towards potential approval for BLU-5937, positioned as a leading treatment option for RCC.

BELLUS Health Inc. (Nasdaq:BLU) announced that CEO Roberto Bellini will participate in a fireside chat at the William Blair Biotech Focus Conference on July 11, 2022, at 9:00 a.m. ET. The chat will be prerecorded, and a webcast will be available on the company’s website afterward. BELLUS Health is focused on developing therapeutics for refractory chronic cough (RCC), a condition affecting around 9 million patients in the U.S. The company's candidate, BLU-5937, has completed Phase 2b trials and a Phase 3 program is expected to commence in the second half of 2022.